The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent
Nuclear Medicine and Biology. 2011;38(5):631-636.Abstract
Introduction: 68Ga is a radionuclide of great interest as a positron emitter for positron emission tomography (PET). To develop a new bone-imaging agent with radiogallium, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was chosen as a chelating site and Ga-DOTA complex-conjugated bisphosphonate, which has a high affinity for bone, was prepared and evaluated. Although we are interested in developing 68Ga-labeled bone imaging agents for PET, in these initial studies 67Ga was used because of its longer half-life. Methods: DOTA-conjugated bisphosphonate (DOTA-Bn-SCN-HBP) was synthesized by conjugation of 2-(4-isothiocyanatebenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid to 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (alendronate). 67Ga-DOTA-Bn-SCN-HBP was prepared by coordination with 67Ga, and its in vitro and in vivo evaluations were performed. Results: 67Ga-DOTA-Bn-SCN-HBP was prepared with a radiochemical purity of over 95% without purification. 67Ga-DOTA-Bn-SCN-HBP had great affinity for hydroxyapatite in binding assay. In biodistribution experiments, 67Ga-DOTA-Bn-SCN-HBP accumulated in bone rapidly but was hardly observed in tissues other than bone. Pretreatment of an excess amount of alendronate inhibited the bone accumulation of 67Ga-DOTA-Bn-SCN-HBP. Conclusions: 67Ga-DOTA-Bn-SCN-HBP showed ideal biodistribution characteristics as a bone-imaging agent. These findings should provide useful information on the drug design of bone imaging agents for PET with 68Ga. © 2011 Elsevier Inc.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Kazuma Ogawa; Hidekazu Kawashima; Kazuhiro Shiba; Kohshin Washiyama; Mitsuyoshi Yoshimoto; Yasushi Kiyono; Masashi Ueda; Hirofumi Mori; Hideo SajiNuclear Medicine and Biology. 2009;36(2):129-135.
Kazuma Ogawa; Takahiro Mukai; Daigo Asano; Hidekazu Kawashima; Seigo Kinuya; Kazuhiro Shiba; Kazuyuki Hashimoto; Hirofumi Mori; Hideo SajiJournal of Nuclear Medicine. 2007;48(1):122-127.
Kazuma Ogawa; Hidekazu Kawashima; Seigo Kinuya; Kazuhiro Shiba; Masahisa Onoguchi; Hiroyuki Kimura; Kazuyuki Hashimoto; Akira Odani; Hideo SajiAnnals of Nuclear Medicine. 2009;23(10):843-848.
Appears in this Document